From the trastuzumab era to new target therapies: Beyond revolution

Annals of Oncology

Volumn 18, Issue SUPPL. 6, 2007, Pages

  Barni, Sandro ^a   Petrelli, F ^a   Cabiddu, M ^a   Cazzaniga, M E ^a   Cremonesi, M ^a  

^a TREVIGLIO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AP 23573; AXITINIB; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DOCETAXEL; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PACLITAXEL; PAZOPANIB; PERTUZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; TEMSIROLIMUS; TRASTUZUMAB; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG PENETRATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HUMAN; MONOTHERAPY; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOLID TUMOR; TREATMENT DURATION; DRUG DELIVERY SYSTEM; FEMALE; META ANALYSIS; METABOLISM; METHODOLOGY; NEOPLASM; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; VASCULARIZATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 35748978583     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm214     Document Type: Conference Paper

References (17)

1. Hortobagyi GN. Trastuzumab in the treatment of Breast Cancer. New Engl J Med. 2005; 16, 353:1734-1736.
2. Cobleigh MA, Langmuir VK, Sledge GW et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30 (5 Suppl 16): 117-124.
3. Pegram M, Chan D, Dichmann RA et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. Breast Cancer Res Treat 2006; 100 (Suppl 1): S28 (Abstr 301).
4. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-799.
5. Perez EA, Hillman DW, Kugler JW et al. North Central cancer treatment group (NCCTG) N0432: Phase II trial of docetaxel with capecitabine and bevacizumab as first line chemotherapy for patients with metastatic breast cancer. Breast Cancer Res Treat 2006; 100 (Suppl 1): S104 (Abstr 2069).
6. Miller KD, Wang M, Gralow J et al. A randomised phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). Presented at the 28th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, 8-11 December 2005 2005 (Abstr 3).
7. Geyer CE, Forster JK, Cameron D et al. A phase III randomized open label, international study comparing lapatinib and capecitabine vs. capecitabine in women with refractory advanced or metastatic breast cancer (EGF100151). J Clin Oncol 2006; 24 (23): 3717-3718.
8. Lin NU, Carey LA, Liu MC et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. J Clin Oncol 2006; 24 (Suppl 18): 1047-1057.
9. Stein SH, Gomez HL, Chavez MA et al. Interim results of a phase II randomizedstudy of lapatinib (GW572016) as first-line treatment for patients with FISH-amplified advanced or metastatic breast cancer. Eur J Cancer 2005; 3 (Suppl): 78.
10. Cristofanilli M, Boussen H, Baselga J et al. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC). 29th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas 2006 (Abstr 1).
11. Miller KD, Burstein HJ, Elias AD et al. Phase II study of SU11248, a multitargeted tyrosine kinase inhibitor (TKI) in patients (pts) with previously treated metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2005; 23: 563.
12. Bianchi G, Loibi S, Zamagni C et al. A phase II multicentre uncontrolled trial of sorafenib (BAY 43-9006) in patients with metastatic breast cancer. Eur J Cancer 2005; 3 (2 Suppl): 78 (Abstr 276).
13. Hurwitz H, Dowlati A, Savage S et al. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. J Clin Oncol 2005; 23 (Suppl): 195s (Abstr 3012).
14. Cresta S, Perotti A, Merlini L et al. Combination of paclitaxel and two schedules of gefitinib in patients with metastatic breast cancer. J Clin Oncol 2006; 24 (Suppl 18): (Abstr 10599).
15. Kaur H, Silverman P, Singh D et al. Toxicity and outcome data in a phase II study of weekly docetaxel in combination with erlotinib in recurrent and/or metastatic breast cancer (MBC). J Clin Oncol 2006; 24 (Suppl 18): (Abstr 10623).
16. Carpenter JT, Rocheé H, Campone M et al. Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23 (Suppl 16): (Abstr 564).
17. Cortes J, Baselga J, Kellokumpu-Lehtinen P et al. Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2. J Clin Oncol 2005; 23 (Suppl 16): (Abstr 3068).